BioCryst Pharmaceuticals (BCRX) Gains FDA Approval for ORLADEYO Pediatric Formulation
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years.
FDA
BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric hereditary angioedema patients aged 2 to <12 years.
BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients Aged 2-12
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years, expanding its market reach.
MAIA Biotechnology (MAIA) Receives FDA Fast Track Designation for Ateganosine in NSCLC
MAIA Biotechnology (MAIA) received FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.